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Abstract 
The aim of this study was to evaluate the effect of active immunization against GnRH on 
ovarian activity, plasma progesterone and estradiol concentrations and on estrous 
behavior in adult mares. Eighteen cyclic mares were randomly divided into a treatment 
and control group. Nine mares were immunized twice with 2 mL (400 µg GnRH-protein 
conjugate) of a GnRH-vaccine (Improvac®, CSL Limited, Australia) administered 
intramuscularly, 4 weeks apart. Control mares received the same amount of saline 
solution. Ovaries and uterus of all mares were examined weekly by ultrasonography 
from 3 weeks before to 60 weeks after the first immunization. Thereafter, vaccinated 
mares were evaluated monthly until 100 weeks after the first vaccination. In addition, 
mares were teased with a stallion for assessment of estrous behavior and blood was 
collected for progesterone, estradiol-17β and GnRH antibody titer determination. 
Results demonstrate that vaccination against GnRH significantly (P<0.05) influenced all 
parameters, except estradiol-17β concentration. All vaccinated mares ceased 
reproductive cyclicity (plasma progesterone <1 ng/mL, follicles <3 cm) within 8 weeks 
after the first injection and ovarian activity remained suppressed for a minimum of 23 
weeks. Five mares resumed cyclicity (follicles >3 cm, progesterone >1 ng/mL) while 3 
mares showed only follicular activity (follicles >3 cm) and 1 mare remained completely 
suppressed for the entire duration of the study. In spite of ovarian suppression, 4 mares 
expressed sporadic and 1 mare continuous estrous behavior. All 9 control mares 
showed regular development of large follicles and associated periods of estrous 
behavior during the breeding season. During the winter months, 6 of them became 
acyclic, whereas the other 3 continued showing reproductive cyclicity and estrous 
 behavior. In conclusion, reproductive cyclicity in adult mares can be successfully 
suppressed by immunization against GnRH but the timing of resumption of cyclicity is 
highly variable and estrous behavior may occur in spite of ovarian suppression. 
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1. Introduction 
The suppression of sexual behavior in mares has long been an issue for both 
veterinarians and horse owners. Undesirable behavioral traits, especially during estrus, 
can make a mare difficult to handle and may have detrimental effects on performance. 
There are numerous methods for managing this problem. One of the most wide spread 
is the use of progesterone or progestins to artificially simulate diestrus [1]. However, the 
possibility of a negative effect on the future breeding prospects after repeated use in 
prepubertal fillies has been reported [2] and the short duration of action of this hormone, 
necessitating repeated administration, make its use costly and impractical. More drastic 
means of suppressing estrous behavior are breeding a mare and accepting the ensuing 
break in the mares’ sporting career, or terminating the pregnancy after maternal 
recognition and maintenance of the primary Corpus luteum (CL) [3], which poses ethical 
problems. Ovariectomy is a further alternative, though not always effective, as some 
mares can continue to show estrous signs [4-6], furthermore it carries the disadvantage 
of surgical risk and permanently eliminating a mare’s reproductive potential. Other 
methods of reversible suppression of sexual activity that warrant being mentioned are 
the administration of GnRH antagonists or agonists [7]. The antagonist antarelix has 
been shown to reliably postpone ovulation after administration and increase the inter-
ovulatory interval [8,9]. Treatment with high doses of agonists can effectively 
desensitize the pituitary to GnRH in various species [10]. Horses are on the whole less 
sensitive to down-regulation, however, prolonged or high dose administration can also 
result in increased inter-ovulatory intervals [11,12] and in some individuals even in a 
temporary cessation of ovarian activity [13,14]. As all these treatments require frequent 
administration and generally result in only a short-term effect with highly individual 
responses, their use for behavioral control is limited. 
The manipulation of the reproductive activity of both males and females through the use 
of a GnRH vaccine has been extensively studied in many species, including humans 
and with a wide variety of objectives. In farm animals, this method offers an alternative 
to surgical castration for minimizing sexual and aggressive behavior, suppressing 
reproductive function and preventing pregnancy [15-18]. In wild animals, vaccination 
against GnRH is considered an effective method for population control [19,20]. Its 
application in human medicine is as a treatment for prostate cancer [21]. In the field of 
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equine reproduction the first report of GnRH vaccination was also as a possible 
alternative to surgical castration in either cryptorchid [22] or normal males [23,24]. The 
principal aims were the evaluation of its effectiveness at inhibiting sexual behavior and 
libido while safeguarding the reproductive potential of an animal. The first studies in 
mares [25,26] were aimed primarily at investigating the effect of GnRH vaccination on 
gonadotropin secretion. Observations of follicular activity and estrous behavior were not 
a major part of the experimental design and mares were ovariectomized [25] or the 
study was terminated [26] before the mares returned to normal ovarian cyclicity; neither 
study concentrated on the possibility of using this method as an alternative to 
ovariectomy. Two further studies have been reported [27,28]: one documented effective 
suppression of ovarian function and estrous behavior along with a subsequent reversal 
of these effects in six 2-year-old fillies [27]; the second study on mature mares showed 
a greater individual variation and less reliability of the vaccination [28] . 
The aim of the present experiment was to investigate the influence of active 
immunization against GnRH on reproductive cyclicity, hormone levels and antibody 
titers in a relatively large group of mature mares. This included evaluation of its 
influence on the ovaries and uterus, the duration of action, effects on estrous behavior 
and adverse reactions to the vaccine. 
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2. Materials and methods 
2.1.  Experimental design 
Eighteen barren light-horse mares, aged between 3 and 17 years, (mean age 7.8 years) 
were used for the experiment. They had variable reproductive histories, but none had 
been bred within the last 2 years. All mares showed normal reproductive cyclicity with 
typical signs of behavioral estrus prior to treatment. The mares were randomly allocated 
to a control and a treatment group of nine mares each (mean age 7.2 and 8.4 years 
respectively). The treatment consisted of two vaccinations four weeks apart using a 
commercially available anti-GnRH vaccine (Improvac®, CSL Limited, Australia) 
developed in Australia to control boar taint in pigs. Improvac® contains a synthetic 
analogue to GnRH linked to a carrier protein and accompanied by an aqueous adjuvant 
(200 µg GnRH-protein conjugate per mL). The dosage used for both initial and booster 
vaccination was 400µg GnRH-protein conjugate (2 mL). Control animals received an 
equivalent volume of saline solution. All injections were applied intramuscularly into the 
left side of the neck. The experiment started at the end of March and initial vaccination 
took place at the end of April. Adverse effects were monitored by twice daily clinical 
examination with particular regard to body temperature, signs of tissue reaction at the 
site of injection and stiffness of the neck. Mares were examined for 3 days after 
vaccination or until all reactions had subsided. 
 
2.2. Ovarian activity, uterine changes and estrous behavior 
The mares’ genital tracts were examined by means of transrectal ultrasonography with 
a 5 MHz linear array probe (Aloka Echocamera SSD-500, Aloka Holding Europe, Zug, 
Switzerland). At each scanning session, the ovaries were measured in two 
perpendicular dimensions. The number and diameters of all follicles larger than 1 cm in 
diameter were recorded and assigned to one of 3 categories: small follicles, <2 cm in 
diameter; medium follicles, 2-3 cm in diameter and large follicles, >3 cm in diameter. 
The diameter of the largest follicle (to the nearest 0.5 cm) present on either ovary was 
recorded separately. The presence of a CL was also noted. The amount of edema in 
the uterine wall was scored as 1 (homogeneous in appearance, non edematous), 2 
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(mildly heterogenous, slightly edematous) or 3 (“wagon wheel” appearance, highly 
edematous) [29]. 
Mares without a clearly visible CL were teased with a stallion after each scanning 
session. Four characteristic estrous signs were noted: tail raising, receptivity to the 
stallion, clitoral eversion and urination. Excessive kicking, flattening of ears and total 
lack of interest in the stallion were judged as negative signs. For a mare to be 
considered as showing typical estrus, at least 3 of 4 positive signs and no negative 
signs had to be observed. Over the course of 64 weeks (3 weeks before to 60 weeks 
after the primary immunization) mares were examined at weekly intervals (period 1). 
Mares in the treatment group that had not yet returned to normal reproductive cyclicity 
after week 60 were examined monthly until they showed a resumption of ovulation 
(period 2). Examinations were discontinued after a maximum of 100 weeks. 
 
2.3. Definition of reproductive activity 
Mares were considered to be acyclic when no large follicles were recorded, no CL was 
visible and progesterone values were lower than 1 ng/mL for at least 4 consecutive 
weeks. If the criteria were fulfilled only during short periods of 1 to 3 weeks, these were 
regarded as periods of temporary follicular quiescence. After an acyclic period, mares 
were judged as having resumed follicular activity when large follicles (>3 cm diameter) 
were recorded. When the mares with follicular activity showed a rise in progesterone 
(plasma progesterone concentration >1 ng/ml) indicating ovulation and formation of a 
functional CL, they were judged as having resumed ovulatory activity. The period of 
ovarian suppression was defined as the number of weeks between cessation of all 
cyclic activity and resumption of follicular activity (no less than 4 weeks). 
 
2.4. Hormone analysis and GnRH antibody titers 
Blood samples (EDTA) were collected at each examination by jugular venipuncture, 
immediately centrifuged (4000 x g, 10 min) and the plasma frozen (-20oC) until analysis. 
Progesterone and estradiol-17ß concentrations were measured using 
electrochemiluminescence immunoassay (Elecsys 2010, Roche Diagnostics, Basel, 
Switzerland). The detection limit of the assay was 0.03 ng/mL for progesterone and 3.1 
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pg/mL for estradiol-17ß. Inter- and intraassay coefficients of variation for progesterone 
were 2.8% and 2.2% respectively and for estradiol-17ß 6.5% and 2.5% respectively. 
Antibody titers against GnRH were determined using a radio ligand binding assay as 
described previously [30]. Results are presented as percentage of total I125-labelled 
GnRH bound at a plasma dilution of 1:40. 
 
2.5. Statistical analysis 
Statistical analysis was performed using the Statview 5.0 software program (SAS 
Institute, Switzerland). A multivariate analysis of variance (ANOVA) was carried out to 
assess the effects of treatment and time on ovarian and uterine parameters as well as 
on plasma progesterone and estradiol concentrations. Differences between the groups 
in weekly parameter means were compared with the unpaired t-test. Values were 
considered to be statistically significant at P<0.05. 
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3. Results 
3.1. Ovarian and uterine changes 
Means (± S.E.M.) of all parameters measured in the treatment and the control group 
from week 1 to 60 are presented in Table 1. 
 
Table 1 
Mean (± S.E.M.) of reproductive activity parameters examined weekly during 60 weeks in  
GnRH immunized (Improvac®) and control mares (n=9, each) and the statistical significance of 
the influence of treatment and time of examination 
 
Parameter GnRH 
immunized 
Control 
 
Treatment 
(P) 
Time 
(P) 
Number of small follicles   4.9 ± 0.20   6.7 ± 0.20 <0.0001 <0.0001 
Number of medium follicles   0.8 ± 0.10   3.0 ± 0.10 <0.0001   0.0004 
Number of large follicles   0.1 ± 0.02   0.8 ± 0.05 <0.0001   0.0228 
Diameter of largest follicle (cm)   1.5 ± 0.04   2.8 ± 0.05 <0.0001 <0.0001 
Ovarian diameter (cm)   4.2 ± 0.03   5.3 ± 0.03 <0.0001 <0.0001 
Number of CL   0.2 ± 0.02   0.7 ± 0.03 <0.0001 <0.0001 
Uterine edema score a)   1.3 ± 0.03   1.7 ± 0.03 <0.0001   0.0113 
Progesterone (ng/mL)   1.2 ± 0.17   6.8 ± 0.36 <0.0001 <0.0001 
Estradiol-17β (pg/mL) 24.4 ± 0.44 24.8 ± 0.35 0.216 <0.0001 
a) 1: homogenous, 2: slightly heterogenous, mildly edematous, 3: wagon wheel appearance, 
highly edematous 
 
Vaccination against GnRH significantly (P<0.05) influenced all parameters, except 
plasma estradiol-17β concentration. Fig. 1 shows the mean number of large follicles (a), 
mean diameter of the largest follicle (b) and mean ovarian diameter (c) in treated and 
control mares from 3 weeks before until 60 weeks after first immunization. 
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Fig. 1. Mean (±S.E.M.) number of large follicles (a), diameter of the largest follicle (b) and 
ovarian diameter (c) in vaccinated (?) and control (?) mares before and after immunization (↓). 
Asterisks indicate a significant difference (P<0.05, unpaired t-test) between groups. 
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Before the first vaccination there were no significant differences between the groups. 
The mean number of large follicles (Fig. 1a) in vaccinated mares decreased rapidly after 
the first vaccination and large follicles were completely absent from weeks 7 to 26. The 
mean number of large follicles remained below 1 until the end of period 1. These 
changes were also reflected by the mean diameters of the largest follicle (Fig. 1b), 
which in vaccinated mares dropped below 2 cm in week 4 and remained between 1 and 
2 cm for 41 consecutive weeks. Mean diameters of the largest follicle in control mares 
only dropped below 2 cm in weeks 35 and 45. The difference between the groups was 
significant (P<0.05) during weeks 5 to 35. Mean ovarian diameters were also 
significantly (P<0.05) lower in vaccinated mares from week 4 to 33 (Fig. 1c). 
Fig. 1 shows that mares in the control group continued normal cyclic activity with regular 
development of large follicles. As the study progressed into the winter months (weeks 
32 to 46), most of the control mares gradually entered seasonal anestrus, showing 
reduced follicular activity and ovarian diameter. The weekly differences between the 2 
groups were no longer significant. The period of ovarian suppression was accompanied 
by an equivalent period in which no CL were observed. In both treatment and control 
groups, the reappearance of a CL was preceded by a notable increase in follicular 
activity and indicated return to cyclic activity. 
Uterine changes mirrored the changes in ovarian activity. The vaccinated mares had 
little ultrasonographically detectable uterine edema from the time when ovarian activity 
ceased until follicular activity recommenced. In control mares, uterine scores of 2 and 3 
were always observed at regular 2 to 4 week intervals, except during the winter months. 
 
3.2. Plasma progesterone and estradiol-17β concentrations 
Fig. 2a shows the mean concentrations of plasma progesterone in treated and control 
mares from 3 weeks before to 60 weeks after first vaccination. Before treatment, the 
mean progesterone values in mares of both groups fluctuated between 1.7 and 11.7 
ng/mL. After initial vaccination, the mean plasma progesterone concentration in the 
treated group fell below 1 ng/mL in week 4 and remained at this level until week 28. 
From week 28 small episodic increases in mean progesterone concentration were 
observed, which became more pronounced towards the end of period 1. In control 
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mares, mean plasma concentration of progesterone rose to 15.4 ng/mL during the 
breeding season and declined during winter months (weeks 32 to 46), remaining below 
2.5 ng/mL from week 37 to 44 (January and February). Values rose again to 17 ng/mL 
as the study progressed into the new breeding season. Significant differences (P<0.05) 
between groups were present continuously during weeks 4 to 30 and at single weeks 
during the following breeding season. 
 
 
Fig. 2. Mean (±S.E.M.) plasma progesterone (a) and estradiol-17β (b) concentrations in 
vaccinated (?) and control (?) mares before and after immunization (↓). Asterisks indicate a 
significant difference (P<0.05, unpaired t-test) between groups. 
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Changes in mean concentrations of plasma estradiol-17β during period 1 are shown in 
Fig. 2b. Before treatment, mares of both groups had mean plasma estradiol-17β values 
fluctuating between 13.8 and 37.3 pg/mL. After the first vaccination the mean estradiol-
17β concentrations in treated mares declined and fluctuated between 13.4 and 27.8 
pg/mL until week 35. From week 36 to 47 (January to March) a clear increase in mean 
plasma estradiol-17β concentrations occurred in treated mares with values up to 40.9 
pg/mL. Thereafter estradiol-17β concentrations rapidly decreased to levels observed 
before week 36. In control mares mean plasma estradiol-17β concentrations varied 
between 17.0 and 36.9 pg/mL during weeks 1 to 60. Significant differences (P<0.05) 
between groups were mainly observed between week 9 to 26 and 36 to 50. 
 
3.3. Duration of ovarian suppression and effect on estrous behavior 
All 9 immunized mares ceased cycling within 8 weeks of the first vaccination and the 
minimum period of ovarian suppression was 23 weeks. During period 1, three mares 
resumed both follicular (weeks 27, 46, 53) and ovulatory activity (weeks 28, 51, 54). In 
period 2, another two mares resumed both follicular (weeks 80, 96) and ovulatory 
activity (weeks 84, 100). Of the 4 treated mares that did not resume ovulatory activity 
during the study, 3 resumed follicular activity at weeks 48, 64 and 100. Of these, one 
showed regular development of large follicles for over 50 weeks without a progesterone 
rise, and one was destroyed for reasons unrelated to the study shortly after resumption 
of large follicle development. One mare remained completely suppressed for the entire 
duration of the study. 
Six of 9 control mares became acyclic during weeks 33 and 41 (December to January) 
and cyclic activity was reestablished between weeks 45 and 56 (March to May). The 
other three control mares never fulfilled the criteria of acyclicity. Fig. 3 shows the 
plasma progesterone concentration together with the diameter of the largest follicle of 4 
individual mares during period 1. Mare A from the control group shows an acyclic period 
between weeks 31 and 47. Mares B, C and D treated with Improvac® illustrate different 
types of reaction to the vaccine. Mare B showed the shortest period of suppression, 
followed by cyclic activity throughout the winter period, mare C showed a gradual return 
to follicular activity before achieving ovulation and mare D remained suppressed 
throughout period 1. 
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Fig. 3. Individual plasma progesterone concentration (?) and diameter of largest follicle (?) of a 
control mare (A) and 3 vaccinated mares (B,C,D) before and after immunization (↓) during 
period 1. 
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In 4 vaccinated mares, estrous signs were absent during ovarian suppression and the 
first occurrence of large follicles was accompanied by estrous behavior. The other 5 
mares expressed estrous signs that were not obviously related to follicle growth. Three 
of these mares showed sporadic estrous behavior, one was in estrus for several weeks 
before resuming follicular activity, while the last mare displayed estrus continuously 
from week 5 after vaccination until plasma progesterone concentration increased (week 
84). All control mares demonstrated regular periods of estrous behavior throughout the 
study, except during seasonal anestrus. 
 
3.4. Antibody titers 
Antibody titers (Fig. 4) began to rise immediately after the first vaccination in all 9 mares 
and reached peak values 2 to 3 weeks after the booster injection. Maximum titers 
showed large individual variations and ranged between 35 and 70% binding (1:40 
dilution). Thereafter, they slowly decreased to values between 15 to 40% binding at 
week 100 after the first vaccination. Values at resumption of ovulatory activity ranged 
from 24 to 35 % binding. 
 
 
Fig. 4. GnRH antibody titers in 9 mares after GnRH immunization (↓) at weeks 0 and 4 (% 
binding at a 1:40 plasma dilution). 
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3.5. Adverse effects 
Eight of 9 mares, which received 2 ml of Improvac®, showed reactions of varying 
severity, including swelling and pain at the injection site, stiffness of the neck, pyrexia 
and apathy (Table 2). The degree and duration of reactions varied individually and were 
more serious after the booster injection. A mean increase in body temperature was only 
evident on the day after each vaccination (mean 38.8 and 38.7°C). However, individual 
peaks up to 39.8°C were recorded. Swelling and pain was most evident on the second 
day after vaccination. All reactions had subsided by 4 and 5 days after primary and 
booster vaccination, respectively. 
 
Table 2 
Incidence of adverse effects of immunizing mares against GnRH using Improvac® 
 
 
 
 
 
 
 
 
 
 
Number of mares Effect 
Primary immunization Booster immunization 
Number of mares immunized              9              9 
Pyrexia    8 (88.9%) 7 (77.8%) 
Pain at site of injection    4 (44.4%) 7 (77.8%) 
Swelling at site of injection    3 (33.3%) 6 (66.7%) 
Stiffness of the neck              0 7 (77.7%) 
Apathy              0 2 (22.2%) 
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4. Discussion 
The results of this study demonstrate that administration of the GnRH vaccine 
Improvac® to mares elicits clear inhibitory changes in endocrine, ovarian, uterine and 
behavioral parameters.  
The effect of immunization against GnRH on ovarian activity was dramatic and rapid, 
and allowed clear differentiation between treated and control mares. Follicular 
development decreased such that by 4 weeks after the first vaccination, the number of 
medium and large follicles differed significantly between the treatment and control 
group. The variation in the amount of time (2-7 weeks) from vaccination to cessation of 
ovarian activity was probably due to immunization at different stages of the cycle. In 
mares with large follicles (estrus), cessation time was longer than in mares vaccinated 
during the luteal phase (diestrus). A similar study [27] carried out with a smaller number 
of mares also showed a rapid response to vaccination with follicular atresia and 
significant reduction in ovarian length 3 to 4 weeks after the first injection. In our study 
the ovarian response was always bilateral and the marked decrease in number and size 
of follicles resulted in ovaries that were significantly smaller than those in the control 
mares for 30 consecutive weeks. Resumption of ovulatory activity was achieved in 5 of 
9 mares and varied between 27 and 100 weeks after the first vaccination. In these 
mares the period of time that elapsed between the first signs of follicular activity and the 
appearance of a progesterone-secreting CL was 1-5 weeks. These results demonstrate 
that resumption of follicular and ovulatory activity after immunization against GnRH is 
highly variable in spite of all mares being immunized at the same time with the same 
dose of the vaccine and despite showing a similar decline of anti-GnRH titers. A highly 
individual duration of ovarian suppression in vaccinated mares was also reported by 
Dalin et al. [28], where one mare showed a large time lapse between resumption of 
follicular activity and first ovulation and another was completely suppressed for 
approximately 14 months. The suppression of ovarian activity is brought about by the 
binding of endogenous GnRH to circulating antibodies, preventing GnRH from binding 
to receptors in the anterior pituitary. Studies on mares have shown that secretion (and 
possibly production) of LH is highly dependent on GnRH, while FSH secretion is at least 
partially independent of GnRH stimulation [25,26]. Therefore, the growth of small antral 
follicles that we observed in all vaccinated mares and that has been previously 
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described in mares [26,28], heifers [17] and ewes [31], may be relatively independent of 
GnRH availability. Because of the more comprehensive suppression of LH then of FSH 
achieved by vaccination against GnRH [25], further development, maturation and 
ovulation may be prevented. 
Resumption of follicular and ovulatory activity in vaccinated mares may be comparable 
to the transitional period seen in mares between seasonal anestrus and the breeding 
season [32] where large (≥3 cm) anovulatory follicles grow and regress before an 
ovulatory follicle develops with sufficient estradiol production to increase LH secretion 
and induce ovulation.  
A significant finding of the current study was that 3 mares showed no signs of luteal 
activity despite regular development of large follicles and that one mare showed neither 
luteal activity nor follicle development for 2 years after vaccination. Without having 
conducted further tests we are unable to say whether immunization resulted in reduced 
sensitivity of the pituitary gland to GnRH or decreased pituitary production and / or 
secretion of LH and FSH. Furthermore, we cannot entirely exclude the possibility of 
some degree of permanent impairment of hypothalamic or pituitary function, as 
observed after the immunization of ewes against GnRH early in life [31]. 
Levels of plasma progesterone and estradiol-17β concentration also showed marked 
differences between the treatment and control groups. Plasma progesterone 
concentration is considered the best indicator for the resumption of estrous cycles in 
mares [27,28]. Cyclic activity in control mares was demonstrated by regular 
progesterone increases, which correlated with recent ovulations. In all vaccinated mares 
the indirect effect of GnRH inactivation on LH secretion was best evidenced by the low 
progesterone concentrations (<1 ng/ml), indicating the absence of ovulations, during at 
least 5 months. The effect of vaccination on estradiol-17β concentrations was less 
dramatic. In control mares, levels fluctuated throughout the whole study and higher 
concentrations were observed when the number of large follicles was increased. In 
vaccinated mares, plasma estradiol-17β concentrations generally fluctuated at a lower 
level than in control mares until the end of the breeding season. From January to March 
mean estradiol-17β concentrations in vaccinated mares were significantly higher than in 
control mares due to abnormally elevated levels seen in 3 mares. As the number and 
size of the follicles during this time was not higher than at any other time during period 
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1, it is speculated that the origin of the estradiol-17β may be increased production by 
granulosa cells of small and antral follicles. It is also possible that the estradiol was of 
adrenal origin since sexual steroids are also produced by the adrenal cortex in response 
to ACTH [5]. 
The manifestation of estrous behavior in anovulatory mares as seen in this study is a 
phenomenon that has been described after vaccination against GnRH [28], after 
treatment with a GnRH agonist [14] and following ovariectomy [5]. In the absence of 
significant progesterone concentrations, only small amounts of estradiol are needed for 
induction of estrous signs. That estrous behavior in ovariectomized mares was 
successfully suppressed by dexamethasone treatment [5] further underlines the 
possible involvement of sexual steroids originating from the adrenal cortex.  
All mares showed an immediate and distinct antibody response after the first 
vaccination with peak levels obtained 2 to 3 weeks after the booster injection. The titer 
decline was similar in all mares, with a rapid fall during the first few weeks followed by a 
steady decline until 100 weeks after the first vaccination. Antibody titers were not clearly 
related to the duration or the degree of ovarian suppression and titers at reversal varied 
considerably. Other studies in mares [26,28], heifers [17] and ewes [33] also report a 
large variation in antibody response, duration of suppression of reproductive activity and 
antibody titer at reversal. It may be concluded that thresholds at which antibody titers 
retain effectiveness are variable between individuals, and may well be related to genetic 
factors and the individuals’ specific immune response [33]. 
The adverse effects to vaccination with Improvac® were quite severe, similar to those 
described by Dalin et al. in mares [28] and Dowsett at al. in stallions [23] using different 
vaccine formulations. Improvac®, originally developed to control boar taint in pigs has 
been shown to be well tolerated in pigs [34,35]. The high incidence of adverse effects 
using Improvac® in horses may either be caused by the adjuvant or the carrier protein 
present in the vaccine. A new vaccine (EquityTM, Pfizer Animal Health, Australia), with a 
modified adjuvant and carrier protein has been designed specifically for use in the horse 
and is well tolerated (authors: unpublished observations). 
In conclusion, this study demonstrates that reproductive cyclicity in adult mares can be 
reliably suppressed by active immunization against GnRH. However, the duration of the 
inhibitory effect is highly variable, not clearly related to GnRH antibody titers and 
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resumption of ovulatory activity may require more than 100 weeks. Moreover, ovarian 
suppression does not always prevent the occurrence of sexual behavior. Because of the 
failure of some mares in this study to return to reproductive cyclicity, it would be of 
practical significance to determine the long-term effects of repeated vaccination on the 
fertility of mares. 
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